This brand name is authorized in Nigeria.
The drug EMBAGREL contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
A74586SNO7 - CLOPIDOGREL
|
|
Clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation. Clopidogrel must be metabolised by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. |
|
2
|
UNII
R16CO5Y76E - ASPIRIN
|
|
Acetylsalicylic acid combines significant advantages such as strong anti-pyretic, analgesic and anti-inflammatory action, that is the measure of comparison with all the newer NSAIDs. |
|
This drug has been approved in Nigeria as follows:
| Identifier | Form | Presentation | Description | Approval |
|---|---|---|---|---|
| C4-1815 | Capsule | Embagrel Capsules CAP 75 mg; 75 mg 10 x 1 x 10's (in blisters) | Capsule | 26/08/2021 |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | C4-1815 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.